Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer

2010409 citationsJournal Articlegreen Open Access

Authors

Daniel C. Danila · Cornell University

Michael J. Morris · Cornell University

Johann S. de Bono · Cornell University

Charles J. Ryan · Cornell University

Samuel R. Denmeade · Cornell University

Matthew R. Smith · Cornell University

Mary-Ellen Taplin ·

Abstract

AA plus prednisone was well tolerated, with encouraging antitumor activity in heavily pretreated CRPC patients. The incidence of mineralocorticoid-related toxicities (hypertension or hypokalemia) was reduced by adding low-dose prednisone. The combination of AA plus prednisone is recommended for phase III investigations.

Topics & Keywords

Prostate Cancer Treatment and Research Hormonal and reproductive studies Cancer, Lipids, and Metabolism

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 28, Issue 9, pp. 1496-1501

DOI: 10.1200/jco.2009.25.9259

Field-Weighted Citation Impact: 61.45